about
Role of iron chelation in improving survival: An integral part of current therapy for myelodysplastic syndromesMolecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?Beyond hypomethylating agents failure in patients with myelodysplastic syndromesSome aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversyManagement of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.Clinical utility of lenalidomide in the treatment of myelodysplastic syndromesComparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromesPlatelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPEfficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB.Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.New themes in the biological functions of 5-methylcytosine and 5-hydroxymethylcytosine.Comparing the Prognostic Value of Risk stratifying Models for Patients with Lower-Risk Myelodysplastic Syndromes: Is one model better?Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.Curcumin reduces the expression of survivin, leading to enhancement of arsenic trioxide-induced apoptosis in myelodysplastic syndrome and leukemia stem-like cellsEmerging biological therapies for the treatment of myelodysplastic syndromes.Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts.Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome.A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database.Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.DNA Methylation Events as Markers for Diagnosis and Management of Acute Myeloid Leukemia and Myelodysplastic Syndrome.Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.Hypomethylating agents in myelodysplastic syndromes and population-level outcomes: a changing landscape or a small dent?More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes.Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients.Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?Relevance of prognostic factors in the decision-making of stem cell transplantation in Myelodysplastic Syndromes.
P2860
Q26765037-CE270872-4476-4602-B0C9-B7AE83E7BB79Q26801573-8C9FB74D-2865-42B9-9EC1-18492DD59333Q26827079-F8E1D89E-5E90-4014-9D1A-6734DDCBA072Q27010653-B9F7CCAD-11DD-4B8D-B124-460394537C48Q30235355-2798E185-1FBE-4D8E-BAA7-9751E3A657D6Q34013786-7439E153-9DAA-4302-9C9D-B3256EF887F3Q34013826-3F3BA2FB-66CD-42FE-A655-87FD0DDC7B5AQ34049017-1CAB8994-0F43-477A-B621-8B20F588771CQ34783754-DAC472E2-E92C-490E-B02C-3AB351C84F5BQ34986440-61E6BC2F-8E4B-45CA-84F7-CEF7229B54E2Q34986462-C9CD370F-B59E-4305-9AF2-83FE12ED7A00Q36503074-E6058455-DD08-40A7-ABEA-1951F68DDDBEQ36642726-F9A91DFF-0FCE-410D-A71B-4D76CA91BE0AQ36655704-5EB7BF05-0042-45A8-B57E-F118552F52FCQ38172875-C38CF40B-2BD6-450D-9FCB-BE3B1893EF40Q38289020-4E3CE66D-F5F2-4DB8-B932-E1A20134924DQ38371732-073E21D1-D4F7-4D77-A7D6-F9037198B129Q38540859-21EA750D-0C84-42D6-928E-2B670066B5FFQ38570399-41A0A5FA-14C7-4681-8B79-DDF2D08124F2Q38651923-9CBCD743-C89B-4B1F-A1F8-70D5D93A44A9Q38687894-A27AFAF3-E36C-42C7-BEED-3452F98DE7A3Q38757359-1FED4AA8-7C20-46EA-AB43-A05C7D1F05E4Q38834981-02812634-7187-40E7-BDAE-D592E96C92CDQ38952962-28E28C86-9F9B-4A2E-B83C-6E8BF82FD96EQ38961023-C9885355-ECE0-4C33-9082-5F6223F77403Q39182177-18FF0083-7304-42FB-B7D7-9B07E5C570C9Q39240258-0AD0176A-1634-4A93-94F8-EE2570ECD2BCQ39968877-A30EAB6A-6037-4720-9152-DA12BA6DDB4CQ40572555-FC663F20-5924-4779-BBF7-02FDAC2A68B9Q40758392-0A539E37-6DD2-476B-B300-8EC1EEACBE28Q41323380-1A65CE81-CCEC-4053-BD9B-16891BB399E2Q42361215-55342C7D-9F04-4272-873C-19A0CEB3364DQ48326336-B5C2BA32-5F31-465E-8B6C-AD428EC69E2CQ49789581-54057031-D063-4023-87CB-F386657ABA92Q50052465-F8AA0B0C-4FA5-4C00-8413-02539F8EA610Q50584145-EC5A3FF4-4182-4635-8E03-D2E7E44E5FCAQ51088597-052852FC-8901-4FC8-AF30-1F2619D31E39Q52941727-D4A89F8E-7C28-48F8-B753-D5BC5FA8A837
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Current therapy of myelodysplastic syndromes
@ast
Current therapy of myelodysplastic syndromes
@en
Current therapy of myelodysplastic syndromes
@nl
type
label
Current therapy of myelodysplastic syndromes
@ast
Current therapy of myelodysplastic syndromes
@en
Current therapy of myelodysplastic syndromes
@nl
prefLabel
Current therapy of myelodysplastic syndromes
@ast
Current therapy of myelodysplastic syndromes
@en
Current therapy of myelodysplastic syndromes
@nl
P2860
P1433
P1476
Current therapy of myelodysplastic syndromes
@en
P2093
Amer M Zeidan
Steven D Gore
P2860
P304
P356
10.1016/J.BLRE.2013.07.003
P577
2013-07-27T00:00:00Z